Dysferlinopathy Fibroblasts Are Defective in Plasma Membrane Repair

Overview

Journal PLoS Curr

Specialty General Medicine

Date 2015 Nov 19

PMID 26579332

Citations 9

Authors

Chie Matsuda

Kazuyuki Kiyosue

Ichizo Nishino

Yuichi Goto

Yukiko K Hayashi

Affiliations

Soon will be listed here.

Abstract

Background: Dysferlin is a sarcolemmal protein that is defective in Miyoshi myopathy and limb-girdle muscular dystrophy type 2B, and is involved in sarcolemmal repair. Primary cultured myoblasts and myotubes established from patient muscle biopsies have been widely utilized to explore the molecular mechanism of dysferlinopathy.

Objectives: The purpose of this study was to explore the possible utility of dermal fibroblasts from dysferlin-deficient patients and SJL mice as a tool for studying dysferlinopathy.

Methods: Dysferlin protein expression in fibroblasts from dysferlin-deficient patients and SJL mice was analyzed by immunoblotting and immunocytochemistry. The membrane wound-repair assay was performed on the fibroblasts using a confocal microscope equipped with a UV-laser. The membrane blebbing assay using hypotonic shock, in which normal membrane blebbing is detected only in the presence of dysferlin, was also performed using human and mouse fibroblasts.

Results: Mis-sense mutated dysferlin was expressed at a very low level in fibroblasts from a dysferlinopathy patient, and lower expression level of truncated dysferlin was observed in SJL mouse fibroblast. Fibroblasts from patients with dysferlinopathy and SJL mice showed attenuated membrane repair and did not form membrane blebs in response to hypoosmotic shock. Proteosomal inhibitior increased mis-sense mutated or truncated dysferlin levels, and restored membrane blebbing, however, proteosomal inhibition failed to improve levels of dysferlin with non-sense or frame-shift mutation.

Conclusion: Fibroblasts from dysferlinopathy patients and SJL mice showed attenuated plasma membrane repair, and could be a tool for studying dysferlinopathy.

Citing Articles

The Dysferlinopathies Conundrum: Clinical Spectra, Disease Mechanism and Genetic Approaches for Treatments.

Anwar S, Yokota T Biomolecules. 2024; 14(3).

PMID: 38540676 PMC: 10968265. DOI: 10.3390/biom14030256.

Clinical, Neurophysiological, Radiological, Pathological, and Genetic Features of Dysferlinopathy in Saudi Arabia.

Alharbi N, Matar R, Cupler E, Al-Hindi H, Murad H, Alhomud I Front Neurosci. 2022; 16:815556.

PMID: 35273475 PMC: 8902167. DOI: 10.3389/fnins.2022.815556.

Therapeutic Benefit of Galectin-1: Beyond Membrane Repair, a Multifaceted Approach to LGMD2B.

Vallecillo-Zuniga M, Poulson P, Luddington J, Arnold C, Rathgeber M, Kartchner B Cells. 2021; 10(11).

PMID: 34831431 PMC: 8621416. DOI: 10.3390/cells10113210.

Muscle spindle function in healthy and diseased muscle.

Kroger S, Watkins B Skelet Muscle. 2021; 11(1):3.

PMID: 33407830 PMC: 7788844. DOI: 10.1186/s13395-020-00258-x.

Treatment with galectin-1 improves myogenic potential and membrane repair in dysferlin-deficient models.

Vallecillo-Zuniga M, Rathgeber M, Poulson P, Hayes S, Luddington J, Gill H PLoS One. 2020; 15(9):e0238441.

PMID: 32881965 PMC: 7470338. DOI: 10.1371/journal.pone.0238441.

References

Lennon N, Kho A, Bacskai B, Perlmutter S, Hyman B, Brown Jr R . Dysferlin interacts with annexins A1 and A2 and mediates sarcolemmal wound-healing. J Biol Chem. 2003; 278(50):50466-73. DOI: 10.1074/jbc.M307247200. View

Philippi S, Bigot A, Marg A, Mouly V, Spuler S, Zacharias U . Dysferlin-deficient immortalized human myoblasts and myotubes as a useful tool to study dysferlinopathy. PLoS Curr. 2012; 4:RRN1298. PMC: 3274833. DOI: 10.1371/currents.RRN1298. View

Vafiadaki E, Reis A, Keers S, Harrison R, Anderson L, Raffelsberger T . Cloning of the mouse dysferlin gene and genomic characterization of the SJL-Dysf mutation. Neuroreport. 2001; 12(3):625-9. DOI: 10.1097/00001756-200103050-00039. View

Villegas J, McPhaul M . Establishment and culture of human skin fibroblasts. Curr Protoc Mol Biol. 2008; Chapter 28:Unit 28.3. DOI: 10.1002/0471142727.mb2803s71. View

Han R, Campbell K . Dysferlin and muscle membrane repair. Curr Opin Cell Biol. 2007; 19(4):409-16. PMC: 2144911. DOI: 10.1016/j.ceb.2007.07.001. View

McNeil P, Steinhardt R . Loss, restoration, and maintenance of plasma membrane integrity. J Cell Biol. 1997; 137(1):1-4. PMC: 2139853. DOI: 10.1083/jcb.137.1.1. View

Matsuda C, Kameyama K, Tagawa K, Ogawa M, Suzuki A, Yamaji S . Dysferlin interacts with affixin (beta-parvin) at the sarcolemma. J Neuropathol Exp Neurol. 2005; 64(4):334-40. DOI: 10.1093/jnen/64.4.334. View

Bansal D, Miyake K, Vogel S, Groh S, Chen C, Williamson R . Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature. 2003; 423(6936):168-72. DOI: 10.1038/nature01573. View

Demonbreun A, Fahrenbach J, Deveaux K, Earley J, Pytel P, McNally E . Impaired muscle growth and response to insulin-like growth factor 1 in dysferlin-mediated muscular dystrophy. Hum Mol Genet. 2010; 20(4):779-89. PMC: 3024047. DOI: 10.1093/hmg/ddq522. View

10.

Bittner R, Anderson L, Burkhardt E, Bashir R, Vafiadaki E, Ivanova S . Dysferlin deletion in SJL mice (SJL-Dysf) defines a natural model for limb girdle muscular dystrophy 2B. Nat Genet. 1999; 23(2):141-2. DOI: 10.1038/13770. View

11.

Guo L, Moore S, Forcales S, Engvall E, Shelton G . Evaluation of commercial dysferlin antibodies on canine, mouse and human skeletal muscle. Neuromuscul Disord. 2010; 20(12):820-5. DOI: 10.1016/j.nmd.2010.07.278. View

12.

Marbini A, Bellanova M, Ferrari A, Lodesani M, Gemignani F . Immunohistochemical study of merosin-negative congenital muscular dystrophy: laminin alpha 2 deficiency in skin biopsy. Acta Neuropathol. 1997; 94(2):103-8. DOI: 10.1007/s004010050680. View

13.

Wein N, Avril A, Bartoli M, Beley C, Chaouch S, Laforet P . Efficient bypass of mutations in dysferlin deficient patient cells by antisense-induced exon skipping. Hum Mutat. 2009; 31(2):136-42. DOI: 10.1002/humu.21160. View

14.

Wang B, Yang Z, Brisson B, Feng H, Zhang Z, Welch E . Membrane blebbing as an assessment of functional rescue of dysferlin-deficient human myotubes via nonsense suppression. J Appl Physiol (1985). 2010; 109(3):901-5. PMC: 3774516. DOI: 10.1152/japplphysiol.01366.2009. View

15.

Vainzof M, Anderson L, MCNALLY E, Davis D, Faulkner G, Valle G . Dysferlin protein analysis in limb-girdle muscular dystrophies. J Mol Neurosci. 2001; 17(1):71-80. DOI: 10.1385/JMN:17:1:71. View

16.

Azakir B, Di Fulvio S, Salomon S, Brockhoff M, Therrien C, Sinnreich M . Modular dispensability of dysferlin C2 domains reveals rational design for mini-dysferlin molecules. J Biol Chem. 2012; 287(33):27629-36. PMC: 3431656. DOI: 10.1074/jbc.M112.391722. View

17.

Bashir R, Britton S, Strachan T, Keers S, Vafiadaki E, Lako M . A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat Genet. 1998; 20(1):37-42. DOI: 10.1038/1689. View

18.

Illa I, Gallardo E, Lasa A, Rojas-Garcia R, Palmer J, Gallano P . Distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype. Ann Neurol. 2001; 49(1):130-4. View

19.

Liu J, Aoki M, Illa I, Wu C, Fardeau M, Angelini C . Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet. 1998; 20(1):31-6. DOI: 10.1038/1682. View

20.

Dominov J, Uyan O, Sapp P, McKenna-Yasek D, Nallamilli B, Hegde M . A novel dysferlin mutant pseudoexon bypassed with antisense oligonucleotides. Ann Clin Transl Neurol. 2014; 1(9):703-20. PMC: 4241797. DOI: 10.1002/acn3.96. View